T-Net: Home

Member Login
|
Employer Login

BC Tech News ▼
International ▼
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼

« Sections »
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
« Account Login »
Members
Employers
« Services »
Post Job Listings
Browse Jobs
Advertise

News By Company

Aurinia Pharmaceuticals Inc.

1 - 10 of 54 Results

New Search

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan

Victoria, BC, December 7, 2023--Aurinia Pharmaceuticals Inc. announced that the Company's collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin, a second-generation oral calcineurin inhibitor for the treatment of lupus nephritis (LN).

Snapshot | Profile | News (60) | Follow

Company Snapshot

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)
20-49 Employees In BC (20-49 Employees Total)
Founded: 2013

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results, Q3 Revenue up 60% to $40.8 Million

Victoria, BC, November 6, 2023--Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued its financial results for the three and nine months ended September 30, 2023. Amounts are expressed in U.S. dollars. The company reported net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter.

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

Victoria, BC, September 27, 2023--Aurinia Pharmaceuticals Inc. announced that its Board of Directors has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board.

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Appoints Two New Directors With Deep Experience in BioPharma Leadership, Strategy, Mergers and Acquisitions and Therapeutic Pipelines

Victoria, BC, August 28, 2023--Aurinia Pharmaceuticals Inc. announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the Company, bringing with them decades of combined leadership experience in the pharmaceutical and biotech industry.

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results, Q2 Net Revenue Up 47% YoY to $41.5 Million

Victoria, BC, August 25, 2023---Aurinia Pharmaceuticals Inc. issued its financial results for the three and six months ended June 30, 2023.Q2 Net revenue up 47% YoY to $41.5 million US. Aurinia had cash, cash equivalents and restricted cash and short-term investments of $350.7 million as of June 30, 2023.

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Publishes Long Term Phase 3 Data Showing LUPKYNIS (Voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients

Victoria, BC, July 24, 2023--Aurinia Pharmaceuticals Inc. announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the official peer-reviewed journal of the American College of Rheumatology.

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS (Voclosporin), Receives 15 Years of Drug Exclusivity Protection (Orphan Drug)

Victoria, BC, May 10, 2023--Aurinia Pharmaceuticals Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V (including mixed classes III/V and IV/V) lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results, Q1 Revenue up 59% YoY to US $34.4 Million

Victoria, BC, May 8, 2023--Aurinia Pharmaceuticals Inc. issued its financial results for first quarter ended March 31, 2023. Total net revenue was $34.4 million for the quarter ended March 31, 2023, compared to $21.6 million in the prior year quarter ended March 31, 2022, representing significant growth of 59% year over year. T

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS in the Treatment of Lupus Nephritis Issued by United States

Victoria, BC, April 26, 2023--Aurinia Pharmaceuticals Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia's newly issued U.S. Patent (No. 11,622,991) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS.

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

Victoria, BC, April 18, 2023--Aurinia Pharmaceuticals Inc. has announced promising results from the AURORA Renal Biopsy Sub-Study. LUPKYNIS is a novel agent approved for the treatment of adults with active lupus nephritis (LN).

Snapshot | Profile | News (60) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

1 2 3 4 5 6

Hiring Today

See All Jobs

Latest Tech Jobs

Featured Job: AWS - Cloud Consultant

Ntirety

Senior Software Engineer, Cognitive Services

Sanctuary AI

Project Coordinator Mental Wellness, Lheidli T'enneh (Prince George, BC) /Northern Region

First Nations Health Authority

Senior Cloud Architect - Hybrid Work - Permanent Fulltime

Insurance Corporation of BC

POL SIH 27R - Senior Policy Analyst

BC Public Service

See All Jobs

Registration on or use of this website constitutes acceptance of our Terms of Use.

News
BC Tech News ▼
- Local BC Tech News
- One Week View
- Subscribe to T-Net Direct
International ▼
- All Breaking International Tech News
- Tech Crunch
- Silicon Alley Insider
- VentureBeat
- CNET
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼
- Post News Release on T-Net
- Submit Anonymous News Tip
- T-Net News Submission Guidelines
Account
Member Login
Employer Login
Sections
News
- BC Tech News ▼
- International ▼
- Member Tools ▼
  - Subscribe to T-Net Direct
- Submit News ▼
Events
- All BC Tech Events ▼
- Member Tools ▼
- Post Events ▼
Tech Careers
- Tech Careers Home
- Job Search ▼
- Hot Job of the Week TM
- Post Resume ▼
  - Post Resume
  - Create Cover Letter
- Member Tools ▼
- Employers ▼
  - Employer Login
  - Post New Job
Directory
- Tech Directory Home
- Companies ▼
- Suppliers ▼
- Associations ▼
- Add Profile ▼
Tech Stocks
- BC Tech Stocks ▼
- T-Net 20 Stock Index
- Member Tools ▼
  - Stock Alerts
  - Company Search
- Add Company ▼
  - Add Company
T-Net 100
- T-Net 100 Rankings ▼
- Sector Rankings ▼
- Advertising
Members
- Member Home ▼
- News ▼
- Events ▼
- Careers ▼
- Directory ▼
- Other ▼
Feedback
About T-Net
Services
Post Job Listings
Advertise on T-Net